Rethinking Vaccine Communications
How a radically new approach to COVID-19 vaccine communications could be the key to reopening society In the last week, Pfizer/BioNTech and Moderna both announced results from two COVID-19 Phase 3 clinical trials showing efficacy of greater than 90 percent. According to company press releases, the trials showed no significant safety issues. (Full publication of the data is yet to come, as is standard practice.) This is great news. But as with most things in 2020, it’s complicated....